Properties
What is it?
International Name - Nadroparinum calcium Clinical-pharmacological group - Antithrombotic and anticoagulant agents; direct-acting anticoagulants Solution for injection: in a pre-filled syringe 0.3 ml, in a pack of 10 pcs. 1 syringe Nadroparinum calcium . .2850 IU anti-Xa Other ingredients: calcium hydroxide or dilute hydrochloric acid q.s. to pH 5-7.5 solution, distilled water. Solution for injection: in a pre-filled syringe 0.4 ml, in a pack of 10 pcs. 1 syringe Nadroparinum calcium . . 3800 IU anti-Xa Other ingredients: calcium hydroxide or dilute hydrochloric acid q.s. to pH 5-7.5 solution, distilled water. Solution for injection: in a pre-filled syringe 0.6 ml, in a pack of 10 pcs. 1 syringe Nadroparinum calcium . .5700 IU anti-Xa Other ingredients: calcium hydroxide or dilute hydrochloric acid q.s. to pH 5-7.5, distilled water. Solution for injection: in a pre-filled syringe 0.8 ml, in a pack of 10 pcs. 1 syringe Nadroparinum calcium . .7600 IU anti-Xa Other ingredients: calcium hydroxide or dilute hydrochloric acid q.s. to pH 5-7.5, distilled water. Indications Prevention of thromboembolic complications: - especially in cases associated with general or orthopedic surgery; - in non-surgical patients with high thromboembolic risk (acute respiratory failure, or respiratory infection, acute heart failure) in intensive care unit conditions Treatment of thromboembolic disorders in deep vein thrombosis; Prevention of blood clotting during hemodialysis; Treatment of unstable angina and non-Q wave myocardial infarction. Dosage and administration For the treatment and prevention of thromboembolic diseases, Fraxiparine is administered by subcutaneous injection. For the prevention of blood clotting during hemodialysis, Fraxiparine is injected into the arterial infusion system before each procedure. When administering the drug subcutaneously, the recommended injection site is the anterior-lateral abdominal wall. Alternating left and right sides, the needle is inserted perpendicularly, not at an angle, into a skin fold, which is fixed between the thumb and index finger until the solution is completely injected. Graduated syringes are intended for use with established doses when weight-based adjustments are necessary. It is recommended to use high-precision syringes and very fine calibrated needles (diameter 0.5 mm) for withdrawing Fraxiparine solution from the vial. Prevention of thromboembolic complications General surgery: Fraxiparine is administered once daily at a dose of 0.3 ml for 7 days; otherwise, prophylaxis is carried out during the risk period until the patient's full motor activity is restored. In general surgery, the first dose is administered 2-4 hours before surgery. Orthopedic surgery: The initial dose of Fraxiparine is administered 12 hours before surgery, as well as 12 hours after surgery. Treatment of thromboembolic diseases: Fraxiparine is administered subcutaneously twice daily (every 12 hours) for 10 days, according to the patient's weight. Side effects From the hematopoietic system: rarely thrombocytopenia, eosinophilia, which resolves after discontinuation of treatment. From the blood coagulation system: increased tendency to bleeding. Allergic reactions: local and general reactions are possible, including anaphylactic shock. Local reactions: rarely small hematomas at the injection site. In isolated cases, firm nodules are observed, which do not indicate heparin encapsulation. Nodules disappear after a few days. Very rarely, skin necrosis at the injection site, preceded by redness, infiltrative or painful erythematous spots with or without general symptoms. In such cases, treatment is discontinued. Other side effects: rarely transient increase in transaminases; in isolated cases - reversible hyperkalemia, priapism.